18:45 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
22:31 , Jan 6, 2017 |  BC Week In Review  |  Company News

Bird Rock, J&J deal

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Bird Rock to develop the biotech's namacizumab . The antibody targets cannabinoid CB1 receptor (CNR1) and is in Phase I testing in healthy volunteers...
00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Clinical News

Gerilimzumab: Phase I data

A pair of double-blind, placebo-controlled Phase I trials in a total of 50 healthy volunteers showed that single doses of 1, 5, 15 and 30 mg subcutaneous gerilimzumab and once-monthly 5 and 20 mg doses...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Gerilimzumab: Phase I started

RuiYi began a double-blind, placebo-controlled Phase I trial to evaluate single and multiple ascending doses of gerilimzumab in healthy volunteers. RuiYi has rights to develop and commercialize gerilimzumab from arGEN-X under a 2012 deal. arGEN-X...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

RuiYi management update

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Hired: Mark Saad as CFO, formerly CFO of Cytori Therapeutics Inc.  ...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...